Listed below are products currently being commercialized, and a high level timeline\ estimates of future product launches.
| Commercial Product List | ||||
| Short term (fiscal 2013) expectations | ||||
| Name | Status | Owner | ||
| 1 | Phentermine 37.5mg | Launched | Elite | |
| 2 | Hydromorphone 8mg | Launched | Elite | |
| 3 | Lodrane D | Launched | ECR | |
| 4 | Methadone 10mg | Launched | PharmaNet | |
| 5 | Phendimetrazine 10mg | Launched | Mikah | |
| 6 | Naltrexone 50mg | Pending Approval | Elite | |
| 7 | Phentermine 15mg | Approved - Awaiting API | Elite | |
| 8 | Phentermine 30mg | Approved - Awaiting API | Elite | |
| Fiscal 2014 expectations | ||||
| 1 | Undisclosed Generic | Pending Approval | Elite | |
| 2 | Undisclosed ANDA | Pending Approval | Epic | |
| 3 | Lodrane CR 12 & 24 | ECR | ||
| 4 | ANDA\NDA 505b2 product | Elite | ||